New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
18:29 EDTSFM, HEAR, NUAN, CEMP, GSAT, GERN, MTZ, GALE, ICPT, DSTI, CALL, MM, SMG, HALO, TRAKOn The Fly: After Hours Movers
UP AFTER EARNINGS: DealerTrack (TRAK), up 11.3%... DTS Inc. (DSTI), up 12.8%... Globalstar (GSAT), up 1.6%... Halozyme Therapeutics (HALO), up 2.4%. ALSO HIGHER: Intercept Pharmaceuticals (ICPT), up 57.7% after announcing that 46% of OCA group met FLINT endpoint as well as reporting second quarter results... Cempra (CEMP), up 5.8% following Intercept Pharmaceuticals' FLINT announcement... Scotts Miracle-Gro (SMG), up 3.6% after board approves a $500M share repurchase authorization and announces a $2.00 per share special dividend. DOWN AFTER EARNINGS: Galena Biopharma (GALE), down 13.4%... Nuance Communications (NUAN), down 9.7%... Millennial Media (MM), down 7.1%... MasTec (MTZ), down 3.6%... Turtle Beach (HEAR), down 3.5%... magicJack (CALL), down 5.8%... Geron (GERN), down 2.4%. ALSO LOWER: Sprouts Farmers Market (SFM), down 3.7% after filing to sell 15M shares of common stock for holders.
News For TRAK;DSTI;GSAT;HALO;ICPT;CEMP;SMG;GALE;NUAN;MM;MTZ;HEAR;CALL;GERN;SFM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
January 22, 2015
10:03 EDTSFMOn the Fly: Analyst Initiation Summary
Subscribe for More Information
07:30 EDTSFMSprouts Farmers Markets initiated with an Outperform at Cowen
Target $40.
07:17 EDTICPTIntercept price target lowered to $300 from $500 at Deutsche Bank
Subscribe for More Information
January 21, 2015
10:01 EDTSFMOn the Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Ashford Hospitality (AHT) upgraded to Outperform from Neutral at Credit Suisse... BAE Systems (BAESY) upgraded to Buy from Neutral at Goldman... Bazaarvoice (BV) upgraded to Outperform from Market Perform at Cowen... Becton Dickinson (BDX) upgraded to Outperform at Cowen... CVS Health (CVS) upgraded to Buy from Neutral at Goldman... Camden Property (CPT) upgraded to Outperform from Neutral at Credit Suisse... ConocoPhillips (COP) upgraded to Buy from Neutral at BofA/Merrill... Cornerstone OnDemand (CSOD) upgraded to Buy from Neutral at DA Davidson... Cree (CREE) upgraded to Overweight at Stephens... DDR Corp. (DDR) upgraded to Outperform from Neutral at Credit Suisse... EastGroup Properties (EGP) upgraded to Outperform from Neutral at Credit Suisse... Energy Transfer Partners (ETP) upgraded to Outperform from Neutral at Credit Suisse... Esperion (ESPR) upgraded at BofA/Merrill... Exxon Mobil (XOM) upgraded to Outperform from Market Perform at Wells Fargo... FXCM (FXCM) upgraded to Market Perform from Underperform at Keefe Bruyette... Fair Isaac (FICO) upgraded to Overweight from Equal Weight at Barclays... Golar LNG (GLNG) upgraded to Buy from Hold at Nordea... Gran Tierra (GTE) upgraded to Buy at Canaccord... Host Hotels (HST) upgraded to Outperform from Neutral at Credit Suisse... J.M. Smucker (SJM) upgraded to Overweight from Neutral at JPMorgan... Kilroy Realty (KRC) upgraded to Neutral from Underperform at Credit Suisse... Level 3 (LVLT) upgraded to Outperform from Market Perform at Wells Fargo... Lowe's (LOW) upgraded to Overweight from Equal Weight at Morgan Stanley... Michael Kors (KORS) upgraded to Outperform at Cowen... Netflix (NFLX) upgraded at Nomura... Regions Financial (RF) upgraded to Buy from Neutral at Guggenheim... Ruckus Wireless (RKUS) upgraded to Outperform from Market Perform at Northland... Santander Mexico (BSMX) upgraded to Neutral from Underperform at Credit Suisse... Scorpio Tankers (STNG) upgraded to Buy at Canaccord... Sprouts Farmers Markets (SFM) upgraded to Buy from Neutral at BofA/Merrill... Strategic Hotels (BEE) upgraded to Outperform from Neutral at Credit Suisse... The Medicines Co. (MDCO) upgraded to Outperform from Market Perform at Leerink... Whole Foods (WFM) upgraded at Sterne Agee... Wolseley (WOSYY) upgraded to Neutral from Underperform at Exane BNP Paribas.
06:02 EDTSFMSprouts Farmers Markets upgraded to Buy from Neutral at BofA/Merrill
Subscribe for More Information
January 20, 2015
16:09 EDTCALLmagicJack announces beta testing on U.S. texting APP and America/Mexico APP
magicJack VocalTec announced that it is in beta testing on two APPs in the U.S. and Mexico, respectively. The magicJack U.S. texting APP is currently in beta testing on iOS by several thousand users and is expected to be made available to customers as soon as testing is completed. In Mexico, the "magicJack America" APP is also currently in beta testing on iOS and Android and is being used by several thousand users.
09:38 EDTNUANActive equity options trading
Subscribe for More Information
07:25 EDTGALENoble Financial to hold a conference
Subscribe for More Information
January 14, 2015
18:18 EDTGALEOn The Fly: After Hours Movers
Subscribe for More Information
16:59 EDTGALEGalena, Orexo AB receive "Paragraph IV" patent certification notice from Actavis
Subscribe for More Information
January 13, 2015
10:17 EDTHALOOptions with decreasing implied volatility
Subscribe for More Information
08:49 EDTMTZMasTec win in Mexico a 'significant milestone,' says FBR Capital
Subscribe for More Information
January 12, 2015
16:15 EDTHEARTurtle Beach sees FY14 revenue at low end of $185M-$195M range
Subscribe for More Information
14:35 EDTNUANNuance calls active after blog predicts possible Baidu buyout
Subscribe for More Information
14:12 EDTNUANNuance ticks higher after blog predicts possible Baidu buyout
Subscribe for More Information
09:15 EDTHALOHalozyme sees FY15 revenue $85M-$95M, consensus $97.23M
Subscribe for More Information
09:15 EDTHALOHalozyme anticipates expanding and accelerating PEGPH20 development efforts
Subscribe for More Information
09:01 EDTTRAKDealerTrack says ownership in incadea plc exceeds 98%
Dealertrack Technologies announced that the acceptance conditions have been satisfied and all other conditions to the December 18, 2014, cash offer for the entire issued and to be issued share capital of incadea plc have been satisfied or waived. Accordingly, the offer is unconditional in all respects. With control of more than 98% of the issued share capital of incadea, Dealertrack intends to commence the cancellation of trading of incadea’s shares on the AIM Market of the London Stock Exchange and to initiate procedures to compulsorily acquire the remaining incadea shares that were not tendered into the offer. Following such cancellation, Dealertrack also intends to procure that incadea re-register from a public limited company to a private limited company. Details of the financial impact of the acquisition will be discussed as part of Dealertrack’s fourth-quarter earnings call in late February.
08:13 EDTICPTIntercept plans to initiate PSC Program Biliary Atresia Phase in 2H15
Intercept provided a clinical update on obeticholic acid, or OCA, a novel bile acid analog and first-in-class agonist of the farnesoid X receptor, or FXR, as well as planned 2015 milestones and other general business updates. OCA is currently being developed for the treatment of several chronic liver diseases, including primary biliary cirrhosis, or PBC, nonalcoholic steatohepatitis, or NASH, and primary sclerosing cholangitis, or PSC. The completion of PBC Program NDA and MAA filings planned in 1H15. The NASH Program Phase 3 program initiation planned in 1H15 and Japan Phase 2 trial data expected at the end of 2015. The PSC Program Biliary Atresia: Phase 2 initiation planned in 2H15 and INT-767: Phase 1 initiation planned for the end of 2015. Intercept ended 2014 with approximately $240M in cash and investments. For FY15, the company projects adjusted operating expenses in the range of $180M-$200M, which excludes stock-based compensation and other non-cash items. These expenses will support the clinical development program for OCA in PBC, NASH and PSC, expansion of our clinical, regulatory, medical affairs and commercial infrastructure in the United States and Europe, expansion of OCA manufacturing activities, as well as advancement of INT-767 and other preclinical pipeline programs. Adjusted operating expense, as presented above, is a non-GAAP financial measure. The company anticipates that stock-based compensation expense will represent the most significant non-cash item that is excluded in adjusted operating expenses as compared to operating expenses under GAAP.
07:26 EDTHEARWedbush to hold a meetings at ICR XChange Conference
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use